Loading...

We've got a brand new version of Simply Wall St! Try it out

AdAlta

ASX:1AD
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1AD
ASX
A$20M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

AdAlta Limited, a drug discovery and development company, develops protein therapeutics. The last earnings update was 81 days ago. More info.


Add to Portfolio Compare Print
  • AdAlta has significant price volatility in the past 3 months.
1AD Share Price and Events
7 Day Returns
-4%
ASX:1AD
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-57.1%
ASX:1AD
50.9%
AU Biotechs
16.3%
AU Market
1AD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AdAlta (1AD) -4% -7.7% -4% -57.1% -47.8% -
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • 1AD underperformed the Biotechs industry which returned 50.9% over the past year.
  • 1AD underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
1AD
Industry
5yr Volatility vs Market

1AD Value

 Is AdAlta undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for AdAlta. This is due to cash flow or dividend data being unavailable. The share price is A$0.12.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AdAlta's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AdAlta's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:1AD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.05
ASX:1AD Share Price ** ASX (2019-11-15) in AUD A$0.12
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AdAlta.

ASX:1AD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:1AD Share Price ÷ EPS (both in AUD)

= 0.12 ÷ -0.05

-2.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AdAlta is loss making, we can't compare its value to the Global Biotechs industry average.
  • AdAlta is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does AdAlta's expected growth come at a high price?
Raw Data
ASX:1AD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
133.5%per year
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AdAlta, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AdAlta's assets?
Raw Data
ASX:1AD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.05
ASX:1AD Share Price * ASX (2019-11-15) in AUD A$0.12
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:1AD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:1AD Share Price ÷ Book Value per Share (both in AUD)

= 0.12 ÷ 0.05

2.41x

* Primary Listing of AdAlta.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AdAlta is good value based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess AdAlta's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AdAlta has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1AD Future Performance

 How is AdAlta expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
133.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AdAlta expected to grow at an attractive rate?
  • AdAlta's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • AdAlta's earnings growth is expected to exceed the Australia market average.
  • AdAlta's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:1AD Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:1AD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 133.5%
ASX:1AD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 112.4%
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:1AD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:1AD Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-06-30 30 14 19 1
2020-06-30 2 -3 -3 1
2019-11-18
ASX:1AD Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 4 -6 -6
2019-03-31 3 -5 -5
2018-12-31 2 -4 -4
2018-09-30 2 -4 -4
2018-06-30 2 -4 -4
2018-03-31 2 -4 -4
2017-12-31 2 -4 -4
2017-09-30 2 -4 -3
2017-06-30 2 -4 -3
2017-03-31 1 -3 -3
2016-12-31 1 -2 -3
2016-09-30 1 -2 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AdAlta's earnings are expected to grow significantly at over 20% yearly.
  • AdAlta's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:1AD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from AdAlta Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:1AD Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-06-30 0.12 0.12 0.12 1.00
2020-06-30 -0.02 -0.02 -0.02 1.00
2019-11-18
ASX:1AD Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.05
2019-03-31 -0.04
2018-12-31 -0.04
2018-09-30 -0.04
2018-06-30 -0.04
2018-03-31 -0.04
2017-12-31 -0.04
2017-09-30 -0.04
2017-06-30 -0.03
2017-03-31 -0.04
2016-12-31 -0.06
2016-09-30 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AdAlta will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess AdAlta's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AdAlta has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1AD Past Performance

  How has AdAlta performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AdAlta's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AdAlta does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare AdAlta's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AdAlta's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
AdAlta's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AdAlta Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:1AD Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 3.54 -5.92 1.23
2019-03-31 2.78 -4.99 1.25 0.08
2018-12-31 2.02 -4.07 1.27 0.16
2018-09-30 2.02 -3.96 1.23 0.08
2018-06-30 2.02 -3.85 1.19
2018-03-31 1.91 -3.92 1.14 0.35
2017-12-31 1.80 -3.98 1.09 0.70
2017-09-30 1.80 -3.40 0.89 0.35
2017-06-30 1.80 -2.83 0.69
2017-03-31 1.28 -2.79 0.68 0.63
2016-12-31 0.77 -2.74 0.68 1.26
2016-09-30 0.75 -1.95 0.50 0.63
2016-06-30 0.74 -1.16 0.33
2015-06-30 0.89 -1.31 0.30
2014-06-30 0.74 -1.25 0.33
2013-06-30 0.81 -0.76 0.31

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AdAlta has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if AdAlta has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AdAlta improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AdAlta's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AdAlta has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1AD Health

 How is AdAlta's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AdAlta's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AdAlta is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AdAlta has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AdAlta's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • AdAlta has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AdAlta Company Filings, last reported 4 months ago.

ASX:1AD Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 7.49 0.00 5.56
2019-03-31 7.49 0.00 5.56
2018-12-31 4.92 0.00 5.36
2018-09-30 4.92 0.00 5.36
2018-06-30 4.07 0.00 2.31
2018-03-31 4.07 0.00 2.31
2017-12-31 4.46 0.00 5.26
2017-09-30 4.46 0.00 5.26
2017-06-30 7.75 0.00 6.22
2017-03-31 7.75 0.00 6.22
2016-12-31 8.31 0.00 8.78
2016-09-30 8.31 0.00 8.78
2016-06-30 1.17 0.00 0.49
2015-06-30 0.71 0.00 0.03
2014-06-30 0.17 0.00 0.38
2013-06-30 0.27 0.00 0.58
  • AdAlta has no debt.
  • AdAlta has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AdAlta has less than a year of cash runway based on current free cash flow.
  • AdAlta has less than a year of cash runway if free cash flow continues to grow at historical rates of 34.5% each year.
X
Financial health checks
We assess AdAlta's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AdAlta has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1AD Dividends

 What is AdAlta's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AdAlta dividends.
If you bought A$2,000 of AdAlta shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AdAlta's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AdAlta's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:1AD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:1AD Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-06-30
2020-06-30
2019-11-18

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AdAlta has not reported any payouts.
  • Unable to verify if AdAlta's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AdAlta's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AdAlta has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AdAlta's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AdAlta afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AdAlta has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1AD Management

 What is the CEO of AdAlta's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tim Oldham
TENURE AS CEO 0.1 years
CEO Bio

Dr. Timothy Charles Oldham, also known as Tim, BSc(Hons), LLB(Hons), Ph.D., has been Chief Executive Officer and Managing Director and Director of AdAlta Limited since October 14, 2019. He served as President of the Asia-Pacific unit of Hospira Inc. since February 1, 2007. Dr. Oldham has several years in academia and experience in the pharmaceutical industry, holding strategy, business development and marketing positions. He served as Vice President for strategic partnerships and as Head of the Europe, Middle East and Africa unit for Mayne Pharma. He has more than a decade of business development, alliance management and sales and marketing experience in Europe, Asia and Australia acquired in senior management roles with Mayne Pharma. He has been a Non Executive Director of Acrux Limited since October 01, 2013. He has been an Independent Non-Executive Director of iSonea Limited since January 6, 2014. He served as Director of Respiri Limited until December 14, 2017. Before embarking on a successful career with McKinsey and Co., Dr. Oldham qualified as a solicitor and obtained a PhD in Chemistry from Imperial College in London. He holds undergraduate degree from Australian National University.

CEO Compensation
  • Insufficient data for Tim to compare compensation growth.
  • Insufficient data for Tim to establish whether their remuneration is reasonable compared to companies of similar size in Australia.
Management Team Tenure

Average tenure of the AdAlta management team in years:

2.1
Average Tenure
  • The tenure for the AdAlta management team is about average.
Management Team

Tim Oldham

TITLE
CEO, MD & Director
TENURE
0.1 yrs

Dallas Hartman

TITLE
Chief Operating Officer
TENURE
2.1 yrs

Mick Foley

TITLE
Chief Scientific Advisor & Chief Scientific Officer

Cameron Jones

TITLE
Company Secretary
TENURE
2.5 yrs
Board of Directors Tenure

Average tenure and age of the AdAlta board of directors in years:

4.3
Average Tenure
56.5
Average Age
  • The tenure for the AdAlta board of directors is about average.
Board of Directors

Paul Donald MacLeman

TITLE
Chairman
COMPENSATION
A$65K
AGE
53

Tim Oldham

TITLE
CEO, MD & Director
TENURE
0.1 yrs

Mick Foley

TITLE
Chief Scientific Advisor & Chief Scientific Officer

John Chiplin

TITLE
Independent Non-Executive Director
COMPENSATION
A$45K
AGE
60
TENURE
5.5 yrs

James Williams

TITLE
Non-Executive Director
COMPENSATION
A$45K
AGE
49
TENURE
8.9 yrs

Liddy McCall

TITLE
Non-Executive Director
COMPENSATION
A$45K
TENURE
8.9 yrs

Brian Richardson

TITLE
Scientific Advisor

John Westwick

TITLE
Scientific Advisor

Bob Peach

TITLE
Non-Executive Director
COMPENSATION
A$50K
AGE
63
TENURE
3 yrs

Ros Wilson

TITLE
Non Executive Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
18. Sep 19 Sell UBS Asset Management Company 14. Aug 19 16. Sep 19 -529,843 A$0.14 A$-71,552
21. Aug 19 Buy Credit Suisse, Investment Banking and Securities Investments Company 03. Jul 19 03. Jul 19 1,823,388 A$0.15 A$273,508
21. Aug 19 Sell Credit Suisse, Investment Banking and Securities Investments Company 01. Jul 19 16. Aug 19 -1,541,418 A$0.22 A$-208,899
28. Jul 19 Sell Credit Suisse, Investment Banking and Securities Investments Company 29. May 19 12. Jun 19 -87,557 A$0.22 A$-14,865
29. Jul 19 Buy City Castle Pty Ltd Company 19. Jul 18 07. Jun 19 720,000 A$0.31 A$115,214
28. Jul 19 Buy Credit Suisse, Investment Banking and Securities Investments Company 29. May 19 18. Jun 19 7,832,292 A$0.15 A$1,176,754
05. Jul 19 Sell UBS Asset Management Company 03. Jun 19 07. Jun 19 -128,892 A$0.16 A$-20,666
X
Management checks
We assess AdAlta's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AdAlta has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1AD News

Simply Wall St News

AdAlta Limited's (ASX:1AD) Path To Profitability

I’ve put together a brief outline of industry analyst expectations for 1AD, its year of breakeven and its implied growth rate. … See our latest analysis for AdAlta 1AD is bordering on breakeven, according to Biotechs analysts. … This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Simply Wall St -

Do Directors Own AdAlta Limited (ASX:1AD) Shares?

Insider Ownership Of AdAlta The definition of company insiders can be subjective, and does vary between jurisdictions. … Private Company Ownership It seems that Private Companies own 9.6%, of the 1AD stock. … Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Simply Wall St -

Did Changing Sentiment Drive AdAlta's Share Price Down By 17%?

That downside risk was realized by AdAlta Limited (ASX:1AD) shareholders over the last year, as the share price declined 17%. … As a result, we think it's unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. … With that in mind, you can understand why the share price dropped 17% in the last year.

Simply Wall St -

How Financially Strong Is AdAlta Limited (ASX:1AD)?

The direct benefit for AdAlta Limited (ASX:1AD), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is 1AD will have to adhere to stricter debt covenants and have less financial flexibility. … Does 1AD's growth rate justify its decision for financial flexibility over lower cost of capital.

Simply Wall St -

Could The AdAlta Limited (ASX:1AD) Ownership Structure Tell Us Something Useful?

Generally speaking, as a company grows, institutions will increase their ownership. … Our analysis of the ownership of the company, below, shows that. … We can zoom in on the different ownership groups, to learn more about 1AD

Simply Wall St -

Is AdAlta Limited's (ASX:1AD) Balance Sheet A Threat To Its Future?

The direct benefit for AdAlta Limited (ASX:1AD), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is 1AD will have to adhere to stricter debt covenants and have less financial flexibility. … Is financial flexibility worth the lower cost of capital

Simply Wall St -

Is AdAlta Limited's (ASX:1AD) CEO Salary Justified?

Therefore I will use earnings as a proxy of Cobb's performance in the past year. … In the situation of negative earnings, the company may be facing a period of reinvestment and growth, or it can be a signal of some headwind. … Usually I would look at market cap and earnings as a proxy for performance, however, 1AD's negative earnings reduces the effectiveness of this method.

Simply Wall St -

What You Must Know About AdAlta Limited's (ASX:1AD) Major Investors

I am going to take a deep dive into AdAlta Limited’s (ASX:1AD) most recent ownership structure, not a frequent subject of discussion among individual investors. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: While 1AD has a low level of institutional ownership, active hedge funds still hold a significant stake in the company.

Simply Wall St -

AdAlta Limited's (ASX:1AD) Earnings Dropped -45.11%, Did Its Industry Show Weakness Too?

When AdAlta Limited (ASX:1AD) released its most recent earnings update (31 December 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … I use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Each year, for the past half a decade AdAlta's top-line has risen by 17.45% on average, signalling that the company is in a high-growth phase with expenses racing ahead revenues, leading to annual losses.

Simply Wall St -

What Is AdAlta Limited's (ASX:1AD) Financial Position?

The direct benefit for AdAlta Limited (ASX:1AD), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … See our latest analysis for AdAlta Is 1AD right in choosing financial flexibility over lower cost of capital? … Choosing financial flexibility over capital returns make sense if 1AD is a high-growth company.

Simply Wall St -

1AD Company Info

Description

AdAlta Limited, a drug discovery and development company, develops protein therapeutics. The company focuses on developing its lead i-body drug candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has a collaborative partnership with Excellerate Bioscience to advance the development of its i-body pipeline. AdAlta Limited was incorporated in 2006 and is based in Bundoora, Australia.

Details
Name: AdAlta Limited
1AD
Exchange: ASX
Founded: 2006
A$19,716,240
164,302,007
Website: http://www.adalta.com.au
Address: AdAlta Limited
2 Park Drive,
Unit 15,
Bundoora,
Victoria, 3083,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX 1AD Ordinary Shares Australian Securities Exchange AU AUD 22. Aug 2016
CHIA 1AD Ordinary Shares Chi-X Australia AU AUD 22. Aug 2016
Number of employees
Current staff
Staff numbers
0
AdAlta employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:41
End of day share price update: 2019/11/15 00:00
Last estimates confirmation: 2019/08/29
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.